In a report released today, Stephanie Davis from SVB Securities maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $7.76.
According to TipRanks, Davis is an analyst with an average return of -0.7% and a 50.48% success rate. Davis covers the Technology sector, focusing on stocks such as NextGen Healthcare, Tabula Rasa HealthCare, and GoodRx Holdings.
In addition to SVB Securities, GoodRx Holdings also received a Hold from Credit Suisse’s Jonathan Yong in a report issued today. However, on the same day, Barclays maintained a Buy rating on GoodRx Holdings (NASDAQ: GDRX).
The company has a one-year high of $48.05 and a one-year low of $5.62. Currently, GoodRx Holdings has an average volume of 2.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.
Read More on GDRX:
- ACADIA Pharmaceuticals (ACAD) Receives a Hold from Goldman Sachs
- Raymond James Sticks to Its Buy Rating for Health Catalyst (HCAT)
- Upstart Holdings (UPST) Gets a Hold from Piper Sandler
- SVB Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
- RBC Capital Sticks to Their Buy Rating for CarGurus (CARG)